Literature DB >> 18202954

Comparison of the safety and protective efficacy of vaccination with glycoprotein-G-deficient infectious laryngotracheitis virus delivered via eye-drop, drinking water or aerosol.

J M Devlin1, G F Browning, J R Gilkerson, S P Fenton, C A Hartley.   

Abstract

Infectious laryngotracheitis virus (ILTV), an alphaherpesvirus, causes respiratory disease in chickens and is commonly controlled by vaccination with conventionally attenuated virus strains. These vaccines have limitations due to residual pathogenicity and reversion to virulence. To avoid these problems and to better control disease, attention has recently turned towards developing a novel vaccine strain that lacks virulence gene(s). Glycoprotein G (gG) is a virulence factor in ILTV. A gG-deficient strain of ILTV has been shown to be less pathogenic than currently available vaccine strains following intratracheal inoculation of specific pathogen free chickens. Intratracheal inoculation of gG-deficient ILTV has also been shown to induce protection against disease following challenge with virulent virus. Intratracheal inoculation, however, is not suitable for large-scale vaccination of commercial poultry flocks. In this study, inoculation of gG-deficient ILTV via eye-drop, drinking water and aerosol were investigated. Aerosol inoculation resulted in undesirably low levels of safety and protective efficacy. Inoculation via eye-drop and drinking water was safe, and the levels of protective efficacy were comparable with intratracheal inoculation. Thus, gG-deficient ILTV appears to have potential for use in large-scale poultry vaccination programmes when administered via eye-drop or in drinking water.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202954     DOI: 10.1080/03079450701802214

Source DB:  PubMed          Journal:  Avian Pathol        ISSN: 0307-9457            Impact factor:   3.378


  6 in total

Review 1.  Infectious laryngotracheitis virus in chickens.

Authors:  Shan-Chia Ou; Joseph J Giambrone
Journal:  World J Virol       Date:  2012-10-12

2.  Infectious Laryngotracheitis Virus Viral Chemokine-Binding Protein Glycoprotein G Alters Transcription of Key Inflammatory Mediators In Vitro and In Vivo.

Authors:  Mauricio J C Coppo; Joanne M Devlin; Alistair R Legione; Paola K Vaz; Sang-Won Lee; José A Quinteros; James R Gilkerson; Nino Ficorilli; Patrick C Reading; Amir H Noormohammadi; Carol A Hartley
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

3.  Recombinant herpesvirus glycoprotein G improves the protective immune response to Helicobacter pylori vaccination in a mouse model of disease.

Authors:  Louise Baker; Andre M L Chitas; Carol A Hartley; Mauricio J C Coppo; Paola K Vaz; Andrew Stent; James R Gilkerson; Joanne M Devlin; Alison L Every
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

4.  Determination of the minimum protective dose of a glycoprotein-G-deficient infectious laryngotracheitis virus vaccine delivered via eye-drop to week-old chickens.

Authors:  Mesula G Korsa; Joanne M Devlin; Carol A Hartley; Glenn F Browning; Mauricio J C Coppo; José A Quinteros; Carlos A Loncoman; Adepeju E Onasanya; Dulari Thilakarathne; Andrés Diaz-Méndez
Journal:  PLoS One       Date:  2018-12-06       Impact factor: 3.240

5.  Attenuated infectious laryngotracheitis virus vaccines differ in their capacity to establish latency in the trigeminal ganglia of specific pathogen free chickens following eye drop inoculation.

Authors:  Dulari S Thilakarathne; Mauricio J C Coppo; Carol A Hartley; Andrés Diaz-Méndez; José A Quinteros; Omid Fakhri; Paola K Vaz; Joanne M Devlin
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

Review 6.  Viral respiratory diseases (ILT, aMPV infections, IB): are they ever under control?

Authors:  Richard C Jones
Journal:  Br Poult Sci       Date:  2010-02       Impact factor: 2.095

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.